<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361136</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1408</org_study_id>
    <secondary_id>2019-000705-67</secondary_id>
    <nct_id>NCT04361136</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Phototoxic Potential of Delgocitinib Cream After Single Topical Occlusive Application on Healthy Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, randomised, vehicle-controlled, double-blind, within-subject&#xD;
      comparison phase 1 clinical trial. The trial is designed to find out if delgocitinib cream&#xD;
      can cause skin irritation after light exposure in people with healthy skin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will receive all treatments with treatments randomised over test fields.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive skin reaction at 24 hours or 48 hours after irradiation</measure>
    <time_frame>Up to 48 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.&#xD;
The grading for the skin reaction score will be performed according to the following 5-point scale:&#xD;
0 No reaction&#xD;
1 Erythema&#xD;
2 Erythema with dermal infiltrate&#xD;
3 Erythema with papulovesicles&#xD;
4 Erythema with blisters, erosions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive skin reaction at 24 hours after irradiation</measure>
    <time_frame>24 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.&#xD;
The grading for the skin reaction score will be performed according to the following 5-point scale:&#xD;
0 No reaction&#xD;
1 Erythema&#xD;
2 Erythema with dermal infiltrate&#xD;
3 Erythema with papulovesicles&#xD;
4 Erythema with blisters, erosions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive skin reaction at 48 hours after irradiation</measure>
    <time_frame>48 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.&#xD;
The grading for the skin reaction score will be performed according to the following 5-point scale:&#xD;
0 No reaction&#xD;
1 Erythema&#xD;
2 Erythema with dermal infiltrate&#xD;
3 Erythema with papulovesicles&#xD;
4 Erythema with blisters, erosions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of treatment-emergent adverse events from baseline to Day 4</measure>
    <time_frame>From time of first investigational medicinal product application (Day 1) until Day 4</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream</intervention_name>
    <description>Cream for topical application</description>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <other_name>LEO 124249 cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream vehicle</intervention_name>
    <description>The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.</description>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <other_name>LEO 124249 cream vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects aged 18-64 years (inclusive).&#xD;
&#xD;
          -  Fitzpatrick skin type of I, II, or III.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Atopic dermatitis, eczema, psoriasis, acne, dermatitis solaris or suntan that could&#xD;
             interfere with the test field evaluation, hyperpigmentation, multiple naevi, tattoos,&#xD;
             blemishes or dense body hair in the range of the test fields.&#xD;
&#xD;
          -  Any history of or presence of cancerous or precancerous skin lesions.&#xD;
&#xD;
          -  Any other skin disease or other visible skin condition noted on physical examination&#xD;
             which in the investigator's opinion might interfere with the evaluation of the test&#xD;
             field reaction.&#xD;
&#xD;
          -  Known disease that can be induced by ultraviolet (UV) light.&#xD;
&#xD;
          -  Use of any topical or systemic medication which could interfere with the trial&#xD;
             objective within 2 weeks before randomisation until end of trial.&#xD;
&#xD;
          -  Use of drugs which might cause photobiologic or phototoxic reactions within 4 weeks&#xD;
             before randomisation until end of trial.&#xD;
&#xD;
          -  Foreseeable intensive UV light exposure (solar or artificial) to test fields within 4&#xD;
             weeks before randomisation until end of trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioskin Research Center Dermatology</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data is available to request after results of the trial are available on leopharmatrials.com</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

